BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-50. [PMID: 17827452 DOI: 10.1200/JCO.2007.11.5287] [Cited by in Crossref: 75] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Qu Y, Tan HY, Chan YT, Jiang H, Wang N, Wang D. The functional role of long noncoding RNA in resistance to anticancer treatment. Ther Adv Med Oncol 2020;12:1758835920927850. [PMID: 32536982 DOI: 10.1177/1758835920927850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Müller C, Schibli R. Prospects in folate receptor-targeted radionuclide therapy. Front Oncol 2013;3:249. [PMID: 24069581 DOI: 10.3389/fonc.2013.00249] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
3 Valenzuela MM, Neidigh JW, Wall NR. Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel) 2014;3:137. [PMID: 26161298 DOI: 10.4172/2167-7700.1000137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
4 Cuneo KC, Nyati MK, Ray D, Lawrence TS. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther 2015;154:67-77. [PMID: 26205191 DOI: 10.1016/j.pharmthera.2015.07.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
5 Yang C, Lee M, Hao J, Cui X, Guo X, Smal C, Bontemps F, Ma S, Liu X, Engler D, Parker WB, Xu B. Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage. Nucleic Acids Res 2012;40:9621-32. [PMID: 22850745 DOI: 10.1093/nar/gks707] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
6 Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE, Deweese TL, Rodriguez R. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol 2010;86:220-9. [PMID: 20201650 DOI: 10.3109/09553000903419338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
7 Maseki S, Ijichi K, Nakanishi H, Hasegawa Y, Ogawa T, Murakami S. Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma. Mol Clin Oncol 2013;1:918-24. [PMID: 24649271 DOI: 10.3892/mco.2013.159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
8 Al-Ejeh F, Darby JM, Brown MP. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One. 2009;4:e4630. [PMID: 19247485 DOI: 10.1371/journal.pone.0004630] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
9 Brunner TB, Sauer R, Fietkau R. Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiat Oncol 2011;6:88. [PMID: 21794119 DOI: 10.1186/1748-717X-6-88] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol 2013;3:73. [PMID: 23565507 DOI: 10.3389/fonc.2013.00073] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
11 Efferth T, Langguth P. Transport processes of radiopharmaceuticals and -modulators. Radiat Oncol 2011;6:59. [PMID: 21645349 DOI: 10.1186/1748-717X-6-59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
12 Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14:6744-50. [PMID: 18980967 DOI: 10.1158/1078-0432.CCR-08-1032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
13 Im MM, Flanagan SA, Ackroyd JJ, Shewach DS. Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine. Radiat Res 2015;183:114-23. [PMID: 25564718 DOI: 10.1667/RR13807.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Karlsson H, Senkowski W, Fryknäs M, Mansoori S, Linder S, Gullbo J, Larsson R, Nygren P. A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget 2019;10:5372-82. [PMID: 31523395 DOI: 10.18632/oncotarget.27166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Bayraktar UD, Diaz LA, Ashlock B, Toomey N, Cabral L, Bayraktar S, Pereira D, Dittmer DP, Ramos JC. Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. Leuk Lymphoma 2014;55:786-94. [PMID: 23837493 DOI: 10.3109/10428194.2013.818142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lee MW, Parker WB, Xu B. New insights into the synergism of nucleoside analogs with radiotherapy. Radiat Oncol 2013;8:223. [PMID: 24066967 DOI: 10.1186/1748-717X-8-223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
17 Harrabi SB, Adeberg S, Winter M, Haberer T, Debus J, Weber KJ. S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro. J Radiat Res 2016;57:110-4. [PMID: 26747201 DOI: 10.1093/jrr/rrv097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Tang J, Wang N, Wu J, Ren P, Li J, Yang L, Shi X, Chen Y, Fu S, Lin S. Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer. Invest New Drugs 2019;37:1146-57. [DOI: 10.1007/s10637-019-00740-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Bezborodova OA, Nemtsova ER, Gevorkov AR, Boyko AV, Venediktova JB, Alekseenko IV, Kostina MB, Monastyrskaya GS, Sverdlov ED, Khmelevskiy EV, Yakubovskaya RI. Antitumor efficacy of combined gene and radiotherapy in animals. Dokl Biochem Biophys 2016;470:345-8. [PMID: 27817015 DOI: 10.1134/S1607672916050112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Rezaee M, Alizadeh E, Cloutier P, Hunting DJ, Sanche L. A single subexcitation-energy electron can induce a double-strand break in DNA modified by platinum chemotherapeutic drugs. ChemMedChem 2014;9:1145-9. [PMID: 24376113 DOI: 10.1002/cmdc.201300462] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
21 Dong X, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog 2012;51:491-9. [PMID: 21681824 DOI: 10.1002/mc.20817] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
22 Pauwels B, Vermorken JB, Wouters A, Ides J, Van Laere S, Lambrechts HA, Pattyn GG, Vermeulen K, Meijnders P, Lardon F. The role of apoptotic cell death in the radiosensitising effect of gemcitabine. Br J Cancer 2009;101:628-36. [PMID: 19672265 DOI: 10.1038/sj.bjc.6605145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
23 Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, Chou CM, Chen CH, Wu J, Wang Y, Liu X, Smith DL, Li H, Liu Z, Warden CD, Su L, Malkas LH, Chung YM, Hu MC, Yen Y. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol 2015;87:996-1005. [PMID: 25814515 DOI: 10.1124/mol.114.094987] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
24 Chen CW, Li Y, Hu S, Zhou W, Meng Y, Li Z, Zhang Y, Sun J, Bo Z, DePamphilis ML, Yen Y, Han Z, Zhu W. DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2). Oncogene 2019;38:2364-79. [PMID: 30518875 DOI: 10.1038/s41388-018-0584-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
25 Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, Vincent M, Min W, Zheng X, Koropatnick J. IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells. PLoS One 2015;10:e0143435. [PMID: 26579709 DOI: 10.1371/journal.pone.0143435] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
26 Garibaldi C, Jereczek-Fossa BA, Marvaso G, Dicuonzo S, Rojas DP, Cattani F, Starzyńska A, Ciardo D, Surgo A, Leonardi MC, Ricotti R. Recent advances in radiation oncology. Ecancermedicalscience 2017;11:785. [PMID: 29225692 DOI: 10.3332/ecancer.2017.785] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
27 Valle L, Katz J, Duffy A, Hueman M, Wang H, Hughes M, Sissung T, Figg W, Citrin D. Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndrome. BJR|case reports. [DOI: 10.1259/bjrcr.20210188] [Reference Citation Analysis]
28 Turnbull T, Douglass M, Williamson NH, Howard D, Bhardwaj R, Lawrence M, Paterson DJ, Bezak E, Thierry B, Kempson IM. Cross-Correlative Single-Cell Analysis Reveals Biological Mechanisms of Nanoparticle Radiosensitization. ACS Nano 2019;13:5077-90. [PMID: 31009200 DOI: 10.1021/acsnano.8b07982] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
29 Glynne-Jones R, Hadaki M, Harrison M. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. J Gastrointest Oncol 2013;4:264-84. [PMID: 23997939 DOI: 10.3978/j.issn.2078-6891.2013.037] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
30 Edwards DM, Speers C, Wahl DR. Targeting Noncanonical Regulators of the DNA Damage Response to Selectively Overcome Cancer Radiation Resistance. Semin Radiat Oncol 2022;32:64-75. [PMID: 34861997 DOI: 10.1016/j.semradonc.2021.09.006] [Reference Citation Analysis]
31 Wang AZ, Tepper JE. Nanotechnology in radiation oncology. J Clin Oncol 2014;32:2879-85. [PMID: 25113769 DOI: 10.1200/JCO.2014.55.0699] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
32 Nezami N, Camacho JC, Kokabi N, El-rayes BF, Kim HS. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin. J Gastrointest Oncol 2019;10:944-56. [DOI: 10.21037/jgo.2019.05.10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
33 Reuvers TGA, Kanaar R, Nonnekens J. DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. Cancers (Basel) 2020;12:E2098. [PMID: 32731592 DOI: 10.3390/cancers12082098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
34 Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H, Simoff M, Li Q, Browning R, Turner FJ, Le Pivert P, Spyratos D, Zarogoulidis K, Celikoglu SI, Celikoglu F, Brachmann J. Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther 2013;7:571-83. [PMID: 23898222 DOI: 10.2147/DDDT.S46393] [Cited by in Crossref: 7] [Cited by in F6Publishing: 26] [Article Influence: 0.8] [Reference Citation Analysis]
35 Qi H, Jiang S, Yu D, Ni H, Hu Q, Zhang J. Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer. Med Oncol. 2015;32:256. [PMID: 26496741 DOI: 10.1007/s12032-015-0704-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]